Anti-Vascular Endothelial Growth Factor Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and

Anti-Vascular Endothelial Growth Factor Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)


Fairfield Market Research, a renowned provider of industry analysis reports, has recently released a comprehensive study on the Anti-Vascular Endothelial Growth Factor Therapeutics Market. The report reveals that the global sales of Anti-Vascular Endothelial Growth Factor (Anti-VEGF) therapies reached US$ 12.1 billion in 2024. The market is projected to experience a steady growth trajectory during the period from 2024 to 2031, slightly higher than historical growth rates.

Key Drivers Fueling Market Growth

The Anti-Vascular Endothelial Growth Factor Therapeutics Market is driven by several key factors:
1. Rising Prevalence of Eye Diseases: Eye diseases such as retinal vein occlusion, diabetic retinopathy, macular edema, and Age-Related Macular Degeneration (AMD) are becoming more common. As the global population ages, the risk of developing these ailments increases, leading to a growing demand for Anti-VEGF therapies.
2. Advancements in Cancer Treatment: Angiogenesis inhibitors, also known as Anti-Vascular Endothelial Growth Factor Inhibitors, play a crucial role in cancer treatment. The pharmaceutical sector's efforts to develop new cancer treatments have contributed to the growth of this market.

Key Challenges and Limitations

Despite the promising prospects, there are challenges and limitations to consider:
1. Tumor Growth Mechanisms: Angiogenesis, the process targeted by Anti-VEGF inhibitors, is not the primary cause of tumor growth in all cases, which limits their effectiveness as a gold standard in cancer treatment.
2. Need for Further Research: Continuous research is required to explore the full potential and limitations of Anti-VEGF therapies in various medical conditions.

Effective Treatment for Diabetic Retinopathy

Anti-Vascular Endothelial Growth Factor Therapeutics have shown significant effectiveness in treating diabetic retinopathy (DR), a common microvascular complication of diabetes. DR is a leading cause of new instances of blindness in working-age individuals. The use of Anti-VEGF inhibitors delivered through intraocular injection has improved visual outcomes in patients with DR.

Impact of Aging Population

The global population aged 60 and above is steadily increasing. The World Health Organization (WHO) estimates that the elderly population surpassed that of children under the age of five. As the elderly population grows, the incidence of eye problems is expected to rise, further boosting the demand for Anti-VEGF therapies.

Market Analysis in Key Countries

U.S. Anti-Vascular Endothelial Growth Factor Therapeutics Market: The U.S. market is driven by factors such as the rising prevalence of cardiovascular illnesses, increased obesity risk, growing disposable incomes, and a competitive landscape with multiple market players.

U.K. Anti-Vascular Endothelial Growth Factor Therapeutics Market: The U.K. market is influenced by evolving healthcare trends and a focus on innovative treatments.

Japan Anti-Vascular Endothelial Growth Factor Therapeutics Market: Japan's market is characterized by a growing aging population and a strong emphasis on healthcare advancements.

Competitive Landscape

Key players in the Anti-Vascular Endothelial Growth Factor Therapeutics Market include F. Hoffmann-La Roche Ltd., Biogen, Pfizer, Inc., CoherusBioSciences, and Amgen, Inc. These companies are at the forefront of research, development, and innovation in the field, driving the growth and evolution of Anti-VEGF therapies.

Market Segments Covered in Anti-Vascular Endothelial Growth Factor Therapeutics Market Industry Analysis

By Product Type
• Eylea
• Lucentis
• Beovu

By DiseaseType
• Macular Edema
• Diabetic Retinopathy
• Retinal Vein Occlusion
• Age-related Macular Degeneration

By Region
• North America
• Latin America
• Europe
• APAC
• MEA

Please note: The PDF e-mail from publisher version of this report is for a global site license. Delivery Timelines - 5 working days.


1. Executive Summary
1.1. Global Anti-Vascular Endothelial Growth Factor Therapeutics Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Global Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook, 2018 – 2031
3.1. Global Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook, by Product Type, Value (US$ Bn), 2018 – 2031
3.1.1. Key Highlights
3.1.1.1. Eylea
3.1.1.2. Lucentis
3.1.1.3. Beovu
3.2. Global Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook, by Disease Type, Value (US$ Bn), 2018 – 2031
3.2.1. Key Highlights
3.2.1.1. Macular Edema
3.2.1.2. Diabetic Retinopathy
3.2.1.3. Retinal Vein Occlusion
3.2.1.4. Age-related Macular Degeneration
3.3. Global Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook, by Region, Value (US$ Bn), 2018 – 2031
3.3.1. Key Highlights
3.3.1.1. North America
3.3.1.2. Europe
3.3.1.3. Asia Pacific
3.3.1.4. Latin America
3.3.1.5. Middle East & Africa
4. North America Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook, 2018 – 2031
4.1. North America Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook, by Product Type, Value (US$ Bn), 2018 – 2031
4.1.1. Key Highlights
4.1.1.1. Eylea
4.1.1.2. Lucentis
4.1.1.3. Beovu
4.2. North America Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook, by Disease Type, Value (US$ Bn), 2018 – 2031
4.2.1. Key Highlights
4.2.1.1. Macular Edema
4.2.1.2. Diabetic Retinopathy
4.2.1.3. Retinal Vein Occlusion
4.2.1.4. Age-related Macular Degeneration
4.2.2. BPS Analysis/Market Attractiveness Analysis
4.3. North America Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook, by Country, Value (US$ Bn), 2018 – 2031
4.3.1. Key Highlights
4.3.1.1. U.S. Anti-Vascular Endothelial Growth Factor Therapeutics Market by Product Type, Value (US$ Bn), 2018 – 2031
4.3.1.2. U.S. Anti-Vascular Endothelial Growth Factor Therapeutics Market by Disease Type, Value (US$ Bn), 2018 – 2031
4.3.1.3. Canada Anti-Vascular Endothelial Growth Factor Therapeutics Market by Product Type, Value (US$ Bn), 2018 – 2031
4.3.1.4. Canada Anti-Vascular Endothelial Growth Factor Therapeutics Market by Disease Type, Value (US$ Bn), 2018 – 2031
4.3.2. BPS Analysis/Market Attractiveness Analysis
5. Europe Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook, 2018 – 2031
5.1. Europe Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook, by Product Type, Value (US$ Bn), 2018 – 2031
5.1.1. Key Highlights
5.1.1.1. Eylea
5.1.1.2. Lucentis
5.1.1.3. Beovu
5.2. Europe Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook, by Disease Type, Value (US$ Bn), 2018 – 2031
5.2.1. Key Highlights
5.2.1.1. Macular Edema
5.2.1.2. Diabetic Retinopathy
5.2.1.3. Retinal Vein Occlusion
5.2.1.4. Age-related Macular Degeneration
5.2.2. BPS Analysis/Market Attractiveness Analysis
5.3. Europe Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook, by Country, Value (US$ Bn), 2018 – 2031
5.3.1. Key Highlights
5.3.1.1. Germany Anti-Vascular Endothelial Growth Factor Therapeutics Market by Product Type, Value (US$ Bn), 2018 – 2031
5.3.1.2. Germany Anti-Vascular Endothelial Growth Factor Therapeutics Market by Disease Type, Value (US$ Bn), 2018 – 2031
5.3.1.3. U.K. Anti-Vascular Endothelial Growth Factor Therapeutics Market by Product Type, Value (US$ Bn), 2018 – 2031
5.3.1.4. U.K. Anti-Vascular Endothelial Growth Factor Therapeutics Market by Disease Type, Value (US$ Bn), 2018 – 2031
5.3.1.5. France Anti-Vascular Endothelial Growth Factor Therapeutics Market by Product Type, Value (US$ Bn), 2018 – 2031
5.3.1.6. France Anti-Vascular Endothelial Growth Factor Therapeutics Market by Disease Type, Value (US$ Bn), 2018 – 2031
5.3.1.7. Italy Anti-Vascular Endothelial Growth Factor Therapeutics Market by Product Type, Value (US$ Bn), 2018 – 2031
5.3.1.8. Italy Anti-Vascular Endothelial Growth Factor Therapeutics Market by Disease Type, Value (US$ Bn), 2018 – 2031
5.3.1.9. Turkey Anti-Vascular Endothelial Growth Factor Therapeutics Market by Product Type, Value (US$ Bn), 2018 – 2031
5.3.1.10. Turkey Anti-Vascular Endothelial Growth Factor Therapeutics Market by Disease Type, Value (US$ Bn), 2018 – 2031
5.3.1.11. Russia Anti-Vascular Endothelial Growth Factor Therapeutics Market by Product Type, Value (US$ Bn), 2018 – 2031
5.3.1.12. Russia Anti-Vascular Endothelial Growth Factor Therapeutics Market by Disease Type, Value (US$ Bn), 2018 – 2031
5.3.1.13. Rest of Europe Anti-Vascular Endothelial Growth Factor Therapeutics Market by Product Type, Value (US$ Bn), 2018 – 2031
5.3.1.14. Rest of Europe Anti-Vascular Endothelial Growth Factor Therapeutics Market by Disease Type, Value (US$ Bn), 2018 – 2031
5.3.2. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook, 2018 – 2031
6.1. Asia Pacific Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook, by Product Type, Value (US$ Bn), 2018 – 2031
6.1.1. Key Highlights
6.1.1.1. Eylea
6.1.1.2. Lucentis
6.1.1.3. Beovu
6.2. Asia Pacific Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook, by Disease Type, Value (US$ Bn), 2018 – 2031
6.2.1. Key Highlights
6.2.1.1. Macular Edema
6.2.1.2. Diabetic Retinopathy
6.2.1.3. Retinal Vein Occlusion
6.2.1.4. Age-related Macular Degeneration
6.2.2. Others BPS Analysis/Market Attractiveness Analysis
6.3. Asia Pacific Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook, by Country, Value (US$ Bn), 2018 – 2031
6.3.1. Key Highlights
6.3.1.1. China Anti-Vascular Endothelial Growth Factor Therapeutics Market by Product Type, Value (US$ Bn), 2018 – 2031
6.3.1.2. China Anti-Vascular Endothelial Growth Factor Therapeutics Market by Disease Type, Value (US$ Bn), 2018 – 2031
6.3.1.3. Japan Anti-Vascular Endothelial Growth Factor Therapeutics Market by Product Type, Value (US$ Bn), 2018 – 2031
6.3.1.4. Japan Anti-Vascular Endothelial Growth Factor Therapeutics Market by Disease Type, Value (US$ Bn), 2018 – 2031
6.3.1.5. South Korea Anti-Vascular Endothelial Growth Factor Therapeutics Market by Product Type, Value (US$ Bn), 2018 – 2031
6.3.1.6. South Korea Anti-Vascular Endothelial Growth Factor Therapeutics Market by Disease Type, Value (US$ Bn), 2018 – 2031
6.3.1.7. India Anti-Vascular Endothelial Growth Factor Therapeutics Market by Product Type, Value (US$ Bn), 2018 – 2031
6.3.1.8. India Anti-Vascular Endothelial Growth Factor Therapeutics Market by Disease Type, Value (US$ Bn), 2018 – 2031
6.3.1.9. Southeast Asia Anti-Vascular Endothelial Growth Factor Therapeutics Market by Product Type, Value (US$ Bn), 2018 – 2031
6.3.1.10. Southeast Asia Anti-Vascular Endothelial Growth Factor Therapeutics Market by Disease Type, Value (US$ Bn), 2018 – 2031
6.3.1.11. Rest of Asia Pacific Anti-Vascular Endothelial Growth Factor Therapeutics Market by Product Type, Value (US$ Bn), 2018 – 2031
6.3.1.12. Rest of Asia Pacific Anti-Vascular Endothelial Growth Factor Therapeutics Market by Disease Type, Value (US$ Bn), 2018 – 2031
6.3.2. BPS Analysis/Market Attractiveness Analysis
7. Latin America Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook, 2018 – 2031
7.1. Latin America Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook, by Product Type, Value (US$ Bn), 2018 – 2031
7.1.1. Key Highlights
7.1.1.1. Eylea
7.1.1.2. Lucentis
7.1.1.3. Beovu
7.2. Latin America Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook, by Disease Type, Value (US$ Bn), 2018 – 2031
7.2.1.1. Macular Edema
7.2.1.2. Diabetic Retinopathy
7.2.1.3. Retinal Vein Occlusion
7.2.1.4. Age-related Macular Degeneration
7.2.2. BPS Analysis/Market Attractiveness Analysis
7.3. Latin America Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook, by Country, Value (US$ Bn), 2018 – 2031
7.3.1. Key Highlights
7.3.1.1. Brazil Anti-Vascular Endothelial Growth Factor Therapeutics Market by Product Type, Value (US$ Bn), 2018 – 2031
7.3.1.2. Brazil Anti-Vascular Endothelial Growth Factor Therapeutics Market by Disease Type, Value (US$ Bn), 2018 – 2031
7.3.1.3. Mexico Anti-Vascular Endothelial Growth Factor Therapeutics Market by Product Type, Value (US$ Bn), 2018 – 2031
7.3.1.4. Mexico Anti-Vascular Endothelial Growth Factor Therapeutics Market by Disease Type, Value (US$ Bn), 2018 – 2031
7.3.1.5. Argentina Anti-Vascular Endothelial Growth Factor Therapeutics Market by Product Type, Value (US$ Bn), 2018 – 2031
7.3.1.6. Argentina Anti-Vascular Endothelial Growth Factor Therapeutics Market by Disease Type, Value (US$ Bn), 2018 – 2031
7.3.1.7. Rest of Latin America Anti-Vascular Endothelial Growth Factor Therapeutics Market by Product Type, Value (US$ Bn), 2018 – 2031
7.3.1.8. Rest of Latin America Anti-Vascular Endothelial Growth Factor Therapeutics Market by Disease Type, Value (US$ Bn), 2018 – 2031
7.3.2. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook, 2018 – 2031
8.1. Middle East & Africa Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook, by Product Type, Value (US$ Bn), 2018 – 2031
8.1.1. Key Highlights
8.1.1.1. Eylea
8.1.1.2. Lucentis
8.1.1.3. Beovu
8.2. Middle East & Africa Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook, by Disease Type, Value (US$ Bn), 2018 – 2031
8.2.1. Key Highlights
8.2.1.1. Macular Edema
8.2.1.2. Diabetic Retinopathy
8.2.1.3. Retinal Vein Occlusion
8.2.1.4. Age-related Macular Degeneration
8.2.2. BPS Analysis/Market Attractiveness Analysis
8.3. Middle East & Africa Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook, by Country, Value (US$ Bn), 2018 – 2031
8.3.1. Key Highlights
8.3.1.1. GCC Anti-Vascular Endothelial Growth Factor Therapeutics Market by Product Type, Value (US$ Bn), 2018 – 2031
8.3.1.2. GCC Anti-Vascular Endothelial Growth Factor Therapeutics Market by Disease Type, Value (US$ Bn), 2018 – 2031
8.3.1.3. South Africa Anti-Vascular Endothelial Growth Factor Therapeutics Market by Product Type, Value (US$ Bn), 2018 – 2031
8.3.1.4. South Africa Anti-Vascular Endothelial Growth Factor Therapeutics Market by Disease Type, Value (US$ Bn), 2018 – 2031
8.3.1.5. Egypt Anti-Vascular Endothelial Growth Factor Therapeutics Market by Product Type, Value (US$ Bn), 2018 – 2031
8.3.1.6. Egypt Anti-Vascular Endothelial Growth Factor Therapeutics Market by Disease Type, Value (US$ Bn), 2018 – 2031
8.3.1.7. Nigeria Anti-Vascular Endothelial Growth Factor Therapeutics Market by Product Type, Value (US$ Bn), 2018 – 2031
8.3.1.8. Nigeria Anti-Vascular Endothelial Growth Factor Therapeutics Market by Disease Type, Value (US$ Bn), 2018 – 2031
8.3.1.9. Rest of Middle East & Africa Anti-Vascular Endothelial Growth Factor Therapeutics Market by Product Type, Value (US$ Bn), 2018 – 2031
8.3.1.10. Rest of Middle East & Africa Anti-Vascular Endothelial Growth Factor Therapeutics Market by Disease Type, Value (US$ Bn), 2018 – 2031
8.3.2. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. Manufacturer vs by Disease Type Heatmap
9.2. Company Market Share Analysis, 2023
9.3. Competitive Dashboard
9.4. Company Profiles
9.4.1. F. Hoffmann-La Roche Ltd.
9.4.1.1. Company Overview
9.4.1.2. Product Portfolio
9.4.1.3. Financial Overview
9.4.1.4. Business Strategies and Development
9.4.2. Biogen
9.4.2.1. Company Overview
9.4.2.2. Product Portfolio
9.4.2.3. Financial Overview
9.4.2.4. Business Strategies and Development
9.4.3. Pfizer Inc
9.4.3.1. Company Overview
9.4.3.2. Product Portfolio
9.4.3.3. Financial Overview
9.4.3.4. Business Strategies and Development
9.4.4. CoherusBioSciences
9.4.4.1. Company Overview
9.4.4.2. Product Portfolio
9.4.4.3. Financial Overview
9.4.4.4. Business Strategies and Development
9.4.5. Amgen Inc
9.4.5.1. Company Overview
9.4.5.2. Product Portfolio
9.4.5.3. Financial Overview
9.4.5.4. Business Strategies and Development
9.4.6. Regeneron Pharmaceuticals Inc.
9.4.6.1. Company Overview
9.4.6.2. Product Portfolio
9.4.6.3. Financial Overview
9.4.6.4. Business Strategies and Development
9.4.7. Bayer AG
9.4.7.1. Company Overview
9.4.7.2. Product Portfolio
9.4.7.3. Financial Overview
9.4.7.4. Business Strategies and Development
9.4.8. Novartis AG
9.4.8.1. Company Overview
9.4.8.2. Product Portfolio
9.4.8.3. Financial Overview
9.4.8.4. Business Strategies and Development
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings